Categorynews

Global Nasal Polyps (Nasal Polyposis) Pipeline Review 2020: Therapeutic Analysis of 9 Companies & 6 Drug Profiles – ResearchAndMarkets.com

October 2, 2020 Off By BusinessWire

DUBLIN–(BUSINESS WIRE)–The “Nasal Polyps (Nasal Polyposis) – Pipeline Review, H2 2020” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Nasal Polyps (Nasal Polyposis) – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide also reviews the key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 3, 1 and 1 respectively.

Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

    • (Read more…)

  • The pipeline guide reviews key companies involved in Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Nasal Polyposis) (Ear Nose Throat Disorders)

Key Topics Covered:

Introduction

Report Coverage

  • Nasal Polyps (Nasal Polyposis) – Overview
  • Nasal Polyps (Nasal Polyposis) – Therapeutics Development

Pipeline Overview

  • Pipeline by Companies
  • Products under Development by Companies

Nasal Polyps (Nasal Polyposis) – Therapeutics Assessment

  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type

Nasal Polyps (Nasal Polyposis) – Companies Involved in Therapeutics Development

  • AnaptysBio Inc
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Idorsia Pharmaceutical Ltd
  • Kyowa Kirin Co Ltd
  • Novartis AG
  • OptiNose Inc
  • Pfizer Inc
  • Suzhou Connect Biopharmaceuticals Ltd

Nasal Polyps (Nasal Polyposis) – Drug Profiles

  • ACT-774312 – Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • benralizumab – Drug Profile
  • CBP-201 – Drug Profile
  • etokimab – Drug Profile
  • fevipiprant – Drug Profile
  • fluticasone propionate – Drug Profile

Nasal Polyps (Nasal Polyposis) – Dormant Projects

  • Nasal Polyps (Nasal Polyposis) – Discontinued Products
  • Nasal Polyps (Nasal Polyposis) – Product Development Milestones

Featured News & Press Releases

Appendix

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/85yz4w

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900